Gene Therapy Researchers Find a Viral Barcode to Cross the Blood-Brain Barrier
UNC School of Medicine scientists led by Aravind Asokan, PhD, reveal how certain gene-carrying AAV vectors can penetrate the brain more efficiently to treat brain and spinal cord conditions, while reducing liver payload.
Gene therapies promise to revolutionize the treatment of many diseases, including neurological diseases such as ALS. But the small viruses that deliver therapeutic genes can have adverse side effects at high doses. UNC School of Medicine researchers have now found a structure on these viruses that makes them better at crossing from the bloodstream into the brain – a key factor for administering gene therapies at lower doses for treating brain and spinal disorders.
“This structural ‘footprint’ we found seems to help these viruses get efficiently into the brain, which informs the design of potentially safer brain-targeted gene therapies,” said study senior author Aravind Asokan, PhD, associate professor of genetics.
The study examined adeno-associated viruses (AAVs), the most commonly used virus vectors for delivering gene therapies. The natural forms of these small viruses normally infect people without causing disease. For gene therapies, scientists remove most of the AAV genome, replace it with therapeutic genetic cargo, and inject trillions of copies into the patient.
Click here to read more.
8th Annual EANS Young Neurosurgeons Meeting and EANS Research Course
March 22, 2018 - March 24, 2018; Oxford, United Kingdom
The Society of University Neurosurgeons Annual Meeting
March 22, 2018 - March 25, 2018; Dallas
ASN 2018 Annual Meeting
March 24-28, 2018; Riverside, CA
3rd Annual Principles and Techniques of Complex Spinal Reconstruction: A Hands-on Cadaveric Workshop
March 30, 2018 - March 31, 2018; New York
11th Annual Cervical Spine Research Society Hands-on Cadaver Course
April 12-14, 2018; St. Louis, MO
Be the first to reply using the above form.